What is Wall Street's Target Price for Kazia Therapeutics Ltd (KZIA) Stock Friday?

Friday, August 05, 2022 02:48 PM | InvestorsObserver Analysts

Mentioned in this article

What is Wall Street's Target Price for Kazia Therapeutics Ltd (KZIA) Stock Friday?

Analysts who follow Kazia Therapeutics Ltd (KZIA) on average expect it to gain 696.02% over the next twelve months. Those same analysts give the stock an average rating of Hold. That average rating earns Kazia Therapeutics Ltd an Analyst Ranking of 5, which means it ranks higher than 5 of stocks, based on data compiled by InvestorsObserver.

Wall Street analysts are rating KZIA a Hold today. Find out what this means to you and get the rest of the rankings on KZIA!

See Full KZIA Report

Why are Analyst Ratings Important?

Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected. InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.

What's Happening With Kazia Therapeutics Ltd Stock Today?

Kazia Therapeutics Ltd (KZIA) stock is higher by 12.96% while the S&P 500 has fallen -0.52% as of 2:48 PM on Friday, Aug 5. KZIA is higher by $0.23 from the previous closing price of $1.78 on volume of 12,458,845 shares. Over the past year the S&P 500 is lower by -6.74% while KZIA has fallen -77.52%. KZIA lost -$0.80 per share the over the last 12 months. Click Here to get the full Stock Report for Kazia Therapeutics Ltd stock.